Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal dexmedetomidine for prevention of post-dural puncture headache after elective cesarean section
PACTR202509503374857Phase 2Not yet recruiting
- Sponsor
- Kasr Al Ainy Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexmedetomidine, bupivacaine and Normal Saline-Benha University in post-dural puncture headache (PDPH) (2 arms), sponsored by Kasr Al Ainy Hospital. Primary endpoint: Incidence of post-dural puncture headache. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
dexmedetomidinebupivacaineNormal Saline-Benha University
03
Conditions
post-dural puncture headache (PDPH)
Beyond the preview
Go deeper on PACTR202509503374857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509503374857.